0001415889-23-001757.txt : 20230201
0001415889-23-001757.hdr.sgml : 20230201
20230201215012
ACCESSION NUMBER: 0001415889-23-001757
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230130
FILED AS OF DATE: 20230201
DATE AS OF CHANGE: 20230201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brophy Michael Burkes
CENTRAL INDEX KEY: 0001697362
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37478
FILM NUMBER: 23578653
MAIL ADDRESS:
STREET 1: 201 INDUSTRIAL ROAD, SUITE 410
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Natera, Inc.
CENTRAL INDEX KEY: 0001604821
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 010894487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 13011 MCCALLEN PASS
STREET 2: BUILDING A SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78753
BUSINESS PHONE: 650-249-9090
MAIL ADDRESS:
STREET 1: 13011 MCCALLEN PASS
STREET 2: BUILDING A SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78753
4
1
form4-02012023_090202.xml
X0306
4
2023-01-30
0001604821
Natera, Inc.
NTRA
0001697362
Brophy Michael Burkes
C/O NATERA, INC.
13011 MCCALLEN PASS BUILDING A SUITE 100
AUSTIN
TX
78753
false
true
false
false
CHIEF FINANCIAL OFFICER
Common Stock
2023-01-30
4
S
0
47188
42.0494
D
105499
D
Common Stock
2023-01-30
4
S
0
1509
43.14
D
103990
D
Common Stock
2023-01-31
4
S
0
35000
42.3303
D
68990
D
Common Stock
2023-02-01
4
S
0
4761
42.8053
D
64229
D
Common Stock
2023-02-01
4
S
0
10413
43.8110
D
53816
D
Common Stock
2023-02-01
4
S
0
4152
44.3526
D
49664
D
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2022.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.0396 to $42.1307 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.3323 to $42.3275 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.24 to $43.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.24 to $44.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.24 to $44.59 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Tami Chen, Attorney-in-Fact
2023-02-01